IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Based on our 6-factor quantitative model, GSK plc (GSK) is the stronger stock with a composite score of 74.3/100 and a Buy rating, compared to Solventum Corp (SOLV) at 59.4/100 (Hold). GSK ranks #18 in our universe versus #754 for SOLV, giving it an edge of 14.9 points across quality, value, momentum, investment, stability, and short interest factors.
For the Quality factor — which measures profitability and business quality through metrics like ROE, gross margins, and capital efficiency — GSK leads at 84/100, while SOLV trails at 78/100 (GSK: 84/100, SOLV: 78/100). The 6-point gap indicates a meaningful difference in quality characteristics between these stocks.
For the Value factor — which evaluates whether a stock is cheap or expensive relative to its earnings, book value, and cash flows — SOLV leads at 96/100, while GSK trails at 90/100 (SOLV: 96/100, GSK: 90/100). The 6-point gap indicates a meaningful difference in value characteristics between these stocks.
For the Momentum factor — which captures price trends and institutional sentiment over the trailing 3-12 months — GSK leads at 70/100, while SOLV trails at 41/100 (GSK: 70/100, SOLV: 41/100). The 30-point gap indicates a meaningful difference in momentum characteristics between these stocks.
For the Investment factor — which assesses capital allocation quality including reinvestment rates and asset growth — GSK leads at 67/100, while SOLV trails at 31/100 (GSK: 67/100, SOLV: 31/100). The 36-point gap indicates a meaningful difference in investment characteristics between these stocks.
For the Stability factor — which measures financial health through leverage ratios and price volatility — GSK leads at 89/100, while SOLV trails at 80/100 (GSK: 89/100, SOLV: 80/100). The 10-point gap indicates a meaningful difference in stability characteristics between these stocks.
For the Short Interest factor — which tracks institutional bearish positioning and potential risk from elevated short selling — GSK leads at 53/100, while SOLV trails at 47/100 (GSK: 53/100, SOLV: 47/100). The 6-point gap indicates a meaningful difference in short interest characteristics between these stocks.
Based on our 6-factor model, GSK plc (GSK) is utilizing a stronger overall profile than SOLV, with a Composite Score of 74 vs 59. GSK holds a moderate edge, particularly in Investment and Momentum, though both stocks have merits.
| Overall Rating | ||
| Composite Score | 74 | 59 |
| Rank | #18 | #754 |
| Stars | 4 / 5 | 3 / 5 |
| Action | Buy | Hold |
| Factor Scores | ||
| Quality | 84 | 78 |
| Value | 90 | 96 |
| Momentum | 70 | 41 |
| Stability | 89 | 80 |
| Investment | 67 | 31 |
| Short Interest | 53 | 47 |
| Valuation | ||
| P/E Ratio | — | 2.50 |
| P/B Ratio | — | 2.54 |
| P/S Ratio | — | 1.51 |
| EV/EBITDA | — | 1.75 |
| Dividend Yield | 5.9% | 0.0% |
| Profitability | ||
| ROE | 22.6% | 134.9% |
| ROA | 4.9% | 35.3% |
| Gross Margin | 71.2% | 54.1% |
| Operating Margin | 12.8% | 80.6% |
| Net Margin | 9.4% | 60.4% |
| Growth & Risk | ||
| Revenue Growth | 1.7% | 0.7% |
| Debt/Equity | 124.00 | 103.00 |
| Beta | 0.22 | 0.92 |
| Market | ||
| Market Cap | $72.13B | $12.66B |
Based on our 6-factor quantitative model, GSK currently has the higher composite score (74.3/100, Buy) and ranks #18 in our universe. However, the "better" stock depends on your investment goals, risk tolerance, and time horizon. We recommend reviewing the full factor breakdown above before making a decision.
Our comparison analyzes six quantitative factors: Quality (profitability and business strength, 30% weight), Momentum (price trends, 25%), Value (valuation attractiveness, 15%), Investment (capital allocation, 10%), Stability (financial health, 10%), and Short Interest (institutional positioning, 10%). Each factor is scored 0-100 and combined into a composite score.
SOLV has the higher value score at 96/100 compared to GSK at 90/100. A higher value score indicates the stock trades at a more attractive valuation relative to its earnings, book value, and cash flows.
Our stock rankings and comparisons are updated daily using the latest available market data, financial statements, and price information. Factor scores reflect the most recent quarterly filings and trailing price data.